Archives of Disease in Childhood, 1989, 64, 1403-1409Regular reviewBone disease in preterm infantsN BISHOPDunn Nutritional...
1404    BishopIn the uterus           (i) High blood calcium, phosphate, and calcitonin concentrations with high bone mine...
Bone disease in preterm infants        1405of gastrin after the first feed may be responsible for     tion by osteoblasts....
1406 Bishopsation, and is present as a contaminant in parenteral     in order to supply the needs of other tissues. Thenut...
Bone disease in preterm infants 1407receiving low phosphate diets-for instance, un- rate of mineral crystallisation; photo...
1408 Bishopreports are usually of well infants, fed fully by the      adverse outcome for bone. For infants born toenteral...
Bone disease in preterm infants 1409weeks gestation. A reasonable prophylactic                            Sorcini-Carta M....
Upcoming SlideShare
Loading in...5

Bone disease in preterm infants


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Bone disease in preterm infants

  1. 1. Archives of Disease in Childhood, 1989, 64, 1403-1409Regular reviewBone disease in preterm infantsN BISHOPDunn Nutritional Laboratory, CambridgeNew work in bone physiology and cell biology In well preterm infants, hypocalcaemia will usuallyduring the last decade has made it possible to begin to improve by 24-30 hours of age, with valuesconstruct a model for the bone disease of preterm in the adult normal range attained by 48-60 hours.infants variously labelled rickets, osteopenia, and Factors unrelated to bone metabolism, particularlymetabolic bone disease of prematurity. The model tissue hypoxia with subsequent calcium influx, mayproposed here explains its pathogenesis and its contribute to the low calcium concentrations seen inoutcomes, and suggests a sequence of appropriate the sickest infants, in whom hypocalcaemia is moreinvestigations as well as a scheme of management. likely to persist and be more pronounced.The figure illustrates the basic processes of bone Previous workers have suggested, however, thatmineral metabolism in the perinatal period, and the plasma parathormone concentration does notprovides a framework against which the derange- rise after birth, and that parathormone resistance isment in mineral homoeostasis leading to bone likely to occur in preterm infants. Much of the earlydisease can be more clearly visualised. work on parathormone in the perinatal period was carried out using radioimmunoassays for either theFetal bone mineral homoeostasis carbon or the nitrogen terminal moiety of the molecule. Parathormone is an 84 amino acid peptideMineral accretion rates for both calcium and that is rapidly and continuously synthesised andphosphorus increase throughout pregnancy, reaching almost immediately subjected to intracellulara maxiumum during the third trimester of 3-0-3*7 degradation.6 Inactive fragments and intact mole-mmol/kg/day for calcium and 2-4-2-7 mmol/kg/day cules are stored together and then released,for phosphorus. principally in response to hypocalcaemia. An Fetal plasma calcitonin concentrations are also increase in the amount of active hormone secretedraised in utero2; though this peptide hormone is could remain undetected, as the total terminalknown principally for its hypocalcaemic action, specific assay activity might not change appreciably.there is substantial evidence that it has appreciable More recent studies, however, carried out withanabolic, mineral accreting effects on bone. intact-molecule and active fragment (residues 1-34) In contrast, the principal hormones mediating assays, have shown a two fold to five fold increase inbone resorption in later life, parathormone, and 1, active parathormone secretion during the first 4825 dihydroxycholecalciferol, are found in low con- hours after birth.5 The principal target organs forcentrations in the fetus.2 3 Interestingly, however, the parathormone molecules thus released are boneprolonged low dose administration of these hor- and kidney. In response to parathormone the kidneymones in animals results in increased bone mass and reabsorbs calcium and actively excretes phosphorus.thus both may be actively concerned in the accretion A reasonable indication of the response to para-rather than resorption of mineral in utero.4 thormone would therefore be to monitor urinary output of phosphorus over the first days after birth.The rwst 48 hours The longitudinal changes in whole blood ionised calcium up to the age of 72 hours, and in urinaryAfter ligation of the cord, the supply of calcium, phosphorus excretion up to the age of 5 days werephosphorus, and all other nutrients ceases abruptly. studied in 18 preterm infants. High urinary concen-The continuing demand by bone for calcium en- trations of phosphorus on days 2 and 3 after birthtrains a rapid fall in blood calcium concentrations; were observed; subsequently, the phosphorus lossthe nadir for ionised calcium is usually at about 18 diminished rapidly and by day 5 phosphorus ex-hours of age, slightly before that for total calcium.5 cretion had ceased in most of the infants studied 1403
  2. 2. 1404 BishopIn the uterus (i) High blood calcium, phosphate, and calcitonin concentrations with high bone mineral accretion rates (ii) Low circulating parathormone, and 1,25 dihydroxycholecalciferol concentrationsFirst 48 hours (i) Transplacental calcium infusion ceases, bone accretion continues, and blood calcium concentration falls (ii) Plasma calcitonin surge exacerbates fall in blood calcium concentration (iii) Hypocalcaemia induces parathormone rise in plasma with effects on bone and kidney Renal effects of parathormone Increased production of 1,25 dihydroxycholecalciferol Adaptive reabsorption of calcium with increased phosphate excretion: body phosphorus stores fall Bone effects ofBone effects of parathormone 1,25 dihydroxycholecalciferol Bone resorption Matrix degradation Release of products-some act Calcium, Phosphateas local humoral factors I Potential for further loss of phosphorus in urine Nutrient supplyProduction of bone matrix Bone miineral accretion + Influence of favourable local factors, matrix vesicles New bone formation: remodelling, growth, and mineralisationFigure Outline of processes of bone mineral metabolism in the perinatal period.(unpublished observations). These observations absorption of calcium and phosphorus, but also theparallel results from animal studies of the effects of mobilisation of calcium from bone. 1,25 dihydroxy-exogenously administered parathormone on phos- cholecalciferol has a central role in the maintenancephate metabolism in states of phosphorus repletion of calcium homoeostasis, which is discussed in detailand depletion.4 below. Another important consequence of the action of The release of parathormone is probably poten-parathormone on the kidney is the enhancement of tiated by the apparently paradoxical release of1,25 dihydrocholecalciferol synthesis. 1,25 di- calcitonin almost immediately after birth.7 In post-hydroxycholecalciferol is the most active metabolite natal life calcitonin is secreted postprandially inof vitamin D3 affecting not only the gastrointestinal response to gastrin production, and the initial surge
  3. 3. Bone disease in preterm infants 1405of gastrin after the first feed may be responsible for tion by osteoblasts. The increase in resorptivethe increase in plasma calcitonin concentrations activity initiated by the surge of parathormone afterseen at this time. Calcitonin inhibits the resorptive birth is therefore matched by a concurrent increaseresponse of osteoclasts and so delays the supply of in new bone formation. Though matrix volume iscalcium from bone to the circulation. The postnatal not reduced during this period of intense activity,regulation of calcium homoeostasis is principally net loss of bone mineral will occur if the exogenousachieved by the interlocking actions of para- supply of mineral substrate is inadequate.thormone and 1,25 dihydroxycholecalciferol on In addition to the supply of adequate mineralbone, and by their separate effects on absorption substrate to normally functioning osteoblasts, aand retention of mineral substrate. favourable local environment for bone mineralisa- tion is also crucial to the remodelling and growth ofBone resorption bone; many factors have been identified in labora- tory studies as having a role. In particular, there is aThe isolation and culture of pure cell lines of growing body of evidence to support the part playedosteoblasts and osteoclasts, have enabled rapid by matrix vesicles in the initiation and propagationadvances in our understanding of the underlying of crystallisation. 2processes in bone.9`11 It is now clear that osteoblasts Matrix vesicles are discrete sacs that are derivedand osteoclasts act. together to undertake bone from the osteoblast cell membrane. They areresorption, and that osteoclasts, having no para- composed of a phospholipid bilayer rich in phos-thormone receptors, exert resorptive activity in phatase enzymes including alkaline phosphatase,response to signals from osteoblasts. The specific and they accumulate at the growing front of bone.effects of parathormone on bone are4: increased At the pH of the mineralisation front, alkalineosteoblast permeability to calcium; release of phosphatase functions principally as a phospho-collagenase from osteoblasts; and release of osteo- transferase, transporting phosphate residues thatclast activating factor(s) from osteoblasts, as a result have been cleaved by other phosphatase enzymesof which osteoclasts increase in number and activity. into the vesicles sap. In addition, 1,25 dihydroxycholecalciferol, Calcium enters the vesicle by diffusion, and isproduced in response to the increased concentra- trapped by phosphatidyl serine. The additionaltions of parathormone, exerts synergistic effects on accumulation of phosphate raises the saturation ofbone.9 1 These are: activation of an osteoblastic the vesicle sap to the point where the calcium/calcium pump; increased activation and fusion of the phosphate solubility product is exceeded andmonocyte/macrophage precursors of osteoclasts; crystallisation begins. Electron microscopic picturesproduction by osteoblasts of osteocalcin (Gla have shown the growth of crystals on the innerprotein), which is chemotactic for osteoclasts; leaflet of the vesicle that leads to its subsequenteffects on immune cell function, particularly disruption as the ends of the crystal pierce thelymphocytes, with reduced interleukin 2, and in- bilayered membrane.creased interleukin 1 production, which enhances These crystals then seed into the fluid at theosteoclast formation and activity; and possibly a mineralisation front and, given adequate mineralreduced response of osteoblasts to parathormone substrate there, act as foci for further crystallisation.(reduced cyclic adenosine monophosphate response). The rate of turnover of matrix vesicles with the Thus parathormone and 1,25 dihydroxychole- release of their membrane constituents, therefore,calciferol have complementary actions; the increase reflects the rate of initiation of osteoblast permeability to calcium flux with the Laboratory studies have shown that there areactivation of a specific calcium pump provides an greatly increased numbers of matrix vesicles inacute response to falling ionised calcium concen- rachitic growth plates3; this lends support to thetrations. The recruitment, activation, and fusion of concept that increased alkaline phosphatase activityosteoclast precursors, and their subsequent activity in plasma may represent increased vesicle turnoverin response to osteoblast derived humoral factors, in substrate or vitamin D deficient states.provides a longer term source of calcium. During the early neonatal period the main deter- minants of bone remodelling, mineralisation, andNew bone formation growth are those that have been discussed in detail above. There are, however, many other factorsThe result of the resorptive process is to produce affecting the fine control of bone homoeostasis,9 11calcium, phosphorus, and breakdown products of of which two are of particular relevance to thebone matrix. These breakdown products are preterm infant.thought to act locally to promote new bone forma- Aluminium is a potent inhibitor of bone minerali-
  4. 4. 1406 Bishopsation, and is present as a contaminant in parenteral in order to supply the needs of other tissues. Thenutrition solutions. 13 Up to 80% of the intravenously biochemical outcomes of these processes are inter-administered load may be retained, and significant linked; reduced concentrations of phosphate indeposition was found in bone after three weeks of urine and plasma precede the increasing urinary lossparenteral feeding. It is possible that aluminium of calcium, and in extreme cases, hypercalcaemia.may exacerbate bone disease in preterm infants fed Raised plasma alkaline phosphatase activity isintravenously. seen principally after 6 weeks of age. Immobility also causes loss of bone mass. Stress Radiological and anthropometric changes occurgenerated electrical potentials have been implicated slowly,15 being seldom evident before 6 weeks ofin the osteogenic process, and prolonged periods of age. l In the long term the principle outcomes forsedation or paralysis during mechanical ventilation bone are linear growth, mineral content, andincrease the possibility of the loss of bone mass. structural integrity. In a large study of preterm infants receiving different diets during the neonatalMineral substrate insufficiency period, we found a significant association between the increase in plasma alkaline phosphatase activityGiven an adequate nutrient supply, remodelling, and a reduction in height achieved at both 9 and 18mineralisation, and growth of bone should proceed months implying that bone disease, reflected bynormally in most infants. For bone disease to increased remodelling activity during the first weeksdevelop, depletion of mineral substrate must occur. of life, had a lasting effect on the infants growthPhosphorus depletion is likely to develop more potential up to the age of 18 months.16rapidly as it may initially be lost in the urine, and If these differences persist, then it is likely that theprotoplasmic metabolic requirements for phos- nutritional deprivation sustained by bone during thisphorus are greater than for calcium (extrapolating apparently critical phase of development has pro-from data on fetal accretion rates and body com- grammed the bone to grow less slowly, as catch upposition studies, 0-6-0-7 mmol/kg/day compared growth would otherwise be observed when dietarywith 0-2-03 mmol/kg/day). sufficiency was achieved.6 Inadequate dietary provision of phosphorus-for The regulatory mechanisms for this adaptiveinstance, the exclusive use of unsupplemented change remain to be elucidated, but could involvehuman milk-compounded by the initial urinary changes in cell number, type, or function, eitherphosphorus losses will result in low tissue phos- locally or systemically.phorus stores, and low circulating concentrations ofphosphorus. Investigation of early bone disease The reduced delivery of phosphorus to the kidneyprevents further appreciable urinary losses and Plasma phosphate concentrations fall gradually fromenhances renal production of 1,25 dihydroxy- 2 mmol/l to 10-O1-5 mmol/l over the first week, andcholecalciferol. The increase in circulating 1,25 often reach a nadir during the second week afterdihydroxycholecalciferol in turn increases gastro- birth (unpublished observations). In infantsintestinal absorption of both calcium and phos- depleted of phosphorus as a result of urinary lossesphorus. In addition, the release of parathormone is and poor intake a further reduction to <1 mmol/linhibited, further reducing the risk of phosphorus may occur, and this has been reported to beloss in the urine. As a corollary, however, renal associated with the later development of bio-reabsorption of calcium is reduced, with consequent chemical and radiological evidence of bone disease.hypercalcuria. The inhibition of parathormone Urinary phosphate excretion initially may be in-release may also slow the process of bone re- creased but by day 5 is usually negligible. Byabsorption; nevertheless, the potent bone resorbing contrast, urinary calcium losses increase and persistactivity of 1,25 dihydroxycholecalciferol will during the period that tissue phosphorus storescontinue to remove some calcium and phosphorus remain depleted. A prolonged absence of phosphatefrom bone. from the urine with persisting calciuria would imply In addition to the phosphorus absorbing and continued tissue phosphorus depletion, and mightretaining processes detailed above, it is possible that be a useful marker to follow sequentially in anhypophosphataemia is a key factor in accelerating individual infant.directly or indirectly the turnover of matrix vesicles The natural history of plasma alkaline phos-and hence increasing plasma alkaline phosphatase phatase activity is to rise over the first 3 weeks andactivity. plateau until the age of 5-6 weeks. Rises that occur If mineral substrate provision continues to be after this are seen principally in infants withinadequate, further substrate will be lost from bone persistently low plasma phosphorus concentrations
  5. 5. Bone disease in preterm infants 1407receiving low phosphate diets-for instance, un- rate of mineral crystallisation; photonabsorptio-supplemented human milk. Increased plasma metry gives an estimation of the amount of mineralalkaline phosphatase activity is widely quoted as actually in bone; and radiographs best show thebeing indicative of bone disease; difficulties arise in abnormal remodelling resulting from an inadequatethe interpretation of results and comparison with provision of mineral substrate for bones that areother centres because of the use of different assay continuing to increase their matrix with widely varying ranges and different Short term anthropometry is useful as a non-units of measurement. Peak concentrations of specific adjunct to the radiological and biochemicalgreater than 7-5 times the maximum adult normal investigations in that a reduced linear growth velo-value for that particular alkaline phosphate assay city at the age of 6 weeks would provide furtherhave been associated with reduced linear growth evidence to support the diagnosis of bone disease. 16velocity in the short term.14 In the work previously For practical purposes, sequential analysis ofreferred to we found an area of demarcation at five urinary calcium and phosphorus losses is likely totimes the maximum normal adult value for plasma provide the earliest evidence of incipient metabolicalkaline phosphatase activity, with appreciable bone disease. If by the age of 3 weeks calciumreductions in growth potential for infants with peak excretion is continuing, with no phosphorus appear-concentrations exceeding this limit.16 ing in the urine despite adopting the prophylactic Radiological changes are usually not seen until measures outlined below, further mineral supple-the age of 6 weeks; reduced bone density, and mentation should be instituted.abnormal bone remodelling in the form of cuppin ,splaying, and fraying of epiphyses may occur, - Managementand-in extreme cases-there may be fractures ofboth ribs and long bones. The interpretation of The management of this condition should essentiallyradiographs is, however, subjective and the use of follow the dictum prevention is better than cure.scoring systems has not improved their predictive The degree and duration of mineral, and in parti-value for minor to moderate degrees of deminerali- cular phosphorus, depletion that will result in bonesation. disease and the amount of supplementation that will Photonabsorptiometry is a quick and accurate prevent it are unknown. It is nevertheless possible tomethod of assessing sequentially the changes in look at the provision of substrate by current feedingbone mineral content at a specific site, usually the practices, formulate estimates of comparative bonedistal radius. 17 Photonabsorptiometry has shown mineral accretion rates, and so assess the minimumthat in infants receiving diets containing little preventative amounts of substrate intake required.mineral substrate, bone mineral content may remain Unsupplemented human milk contains 0-5 mmol/unchanged, or even decrease initially, and then 100 ml of phosphorus. For infants receiving 200increase at a rate much less that attained in the ml/kg/day, and assuming 90-95% retention, 0-9-uterus. By contrast, infants supplied with mineral in 0-95 mmol/kg/day of phosphorus will be delivered.amounts approaching the intrauterine rate can After allowing for basal protoplasmic requirements,maintain the fetal rate of mineral accretion.18 The approximately 0-3 mmol of phosphorus will beuse of photonabsorptiometry is restricted to a few available for deposition in bone mineral. Calciumselected centres, however, and its principle use at and phosphorus accrete at a ratio of 5:3 in bone; uppresent is for research rather than as an aid to to 0-5 mmol/kg of calcium might therefore bediagnosis. deposited-about 15% of the intrauterine accretion Radiographic densitometry is a low dose whole rate.body technique that provides accurate information By contrast, a preterm formula containing 1about the overall mineral state of the skeleton. As mmol/100 ml of phosphorus supplied at 180 ml/kg/yet it has not been applied to preterm infants, but it day should result in a phosphorus retention ofcould provide valuable data for body composition 1- 61-7 mmollkg/day. After allowing for proto-and mineral metabolism studies. plasmic requirements, about 1 mmol/kg/day of It has been often noted that peak alkaline phosphorus is available for bone mineralisation,phosphatase activity rarely occurs at the same complexing with 1-6 mmol/kg/day of calcium-time as radiological evidence of abnormal bone approximately 50% of the intrauterine accretionremodelling, or the degree of bone demineralisation rate. Formulas with higher calcium and phosphorusas measured by photonabsorptiometry. This is contents are available in some countries, and haveessentially a reflection of the intrinsic properties of been used widely without adverse effects. Reportedeach investigation-plasma alkaline phosphatase mineral accretion rates for infants fed these milksactivity is a measure of bone activity, possibly of the approach those achieved in the uterus,8 but the
  6. 6. 1408 Bishopreports are usually of well infants, fed fully by the adverse outcome for bone. For infants born toenteral route by the age of 1 week. In addition, mothers not receiving vitamin D supplementation,concern has been expressed generally that not all of as much as 1200 IU/day may be required. Increasingthe calcium and phosphate in these milks is available the supply of vitamin D3 further may increase thefor absorption, possibly as a result of precipitation short term retention of calcium, particularly in thosebefore feeding. infants in whom the supply of substrate is poor, but Given that protoplasmic requirements may be may also have longer term consequences for boneincreased because of pre-existing tissue phosphorus resorption and remodelling activities. In additiondepletion, particularly in infants who have pre- there may be as yet undefined consequences onviously been intravenously fed, the provision of 1 cellular differentiation in other tissues; vitamin D3 ismmol/100 ml of phosphorus in milk given to preterm a steroid type molecule, and a potent mitogenicinfants should be regarded as an absolute minimum. agent. The addition of phosphorus to expressed human Most preterm infants will not benefit from beingmilk is already common. Buffered neutral phos- given the active metabolites of vitamin D3; thesephate can safely be admixed with human milk over a should be confined to those patients in whom a24 hour period to raise the phosphorus content from vitamin D3 resistant state, for example, X linked0-5 mmolV100 ml to 1-0 mmol/100 ml. hypophosphataemic rickets, has been confirmed. Larger quantities of both calcium and phosphorus Intravenously fed preterm infants are most at riskcan be added to human milk. It is important to add from poor supplies of mineral substrate. The solu-the phosphorus salt (usually disodium phosphate) bility of calcium and phosphorus in parenteralfirst so that it can enter the fat micelles. There is an nutrition solutions depends on a number of factors:appreciable risk of precipitation if calcium (usually the pH and the amino acid composition of thegiven as calcium gluconate/glubionate) is added solution, the calcium salt used, and the temperaturebefore the phosphorus. to which the solution is exposed. As much as 1-6 mmol of phosphorus and 1-35 The more acidic the solution, the greater themmol of calcium can be added in this way. 19 quantity of mineral substrate it can hold, and forAlthough some precipitation does occur, balance most solutions calcium gluconate is more solublestudies indicate that the absorption and retention of than calcium chloride. Recently, amino acid solu-both calcium and phosphorus from such solutions is tions tailored to the requirements of infants havegood. been produced, with claims of improved capacity for The multinutrient fortifiers added to breast milk calcium and phosphate. The testing of thesein some countries rely upon stabilising agents to solutions has not, however, taken account of thehold large quantities of mineral substrate in solu- prolonged exposure to high temperatures (37°C fortion. Problems with precipitation and reduced more than two hours) that may obtain in clinicalabsorption and retention have been reported, practice.however, and in one study20 it was found that The risk of precipitation with line blockage, orretention of substrate from a preterm formula even microembolisation of crystalline particles,exceeded that from a fortified human milk solution. should not be ignored when using solutions withThe use of such fortifiers is still the subject of calcium and phosphate contents near the limit ofintense research, and they cannot be unreservedly solubility. The use of microporous filters within therecommended for general use. line would reduce these risks appreciably. Using The addition of phosphorus to preterm formula is currently available amino acid solutions infused atunlikely to be beneficial as the total amount of 150 mllkg/day, 1-1 mmol/kg/day of phosphorus andcalcium retained and available for bone mineralisa- 1-5 mmol/kg/day of calcium can be administered attion is already completely utilised. Further addition most. Claims of improved solubility and mineralof phosphate may in fact precipitate calcium from delivery using glucose-i-phosphate have been made,the milk solution, further reducing availability of the but the use of an intermediary metabolite for thissubstrate. purpose is still under investigation. Vitamin D3 should be given routinely to all In addition to problems with calcium and phos-preterm infants.2 For infants born in the United phorus delivery, the presence of high concentrationsKingdom whose mothers have received vitamin D of aluminium in some solutions has given rise tosupplementation during pregnancy the current concern about possible inhibition of osteoblasticrecommendations are for 400-1000 IU/day, function in infants receiving prolonged intravenousalthough it should be noted that with adequate feeding.dietary provision of calcium and phosphorus as little In clinical practice, the infants likely to requireas 100 IU/day has been given without obvious mineral supplementation are those of less than 33
  7. 7. Bone disease in preterm infants 1409weeks gestation. A reasonable prophylactic Sorcini-Carta M. Plasma thyrocalcitonin and parathyroidmeasure would be the addition of 0-5 mmol of hormone concentrations in early neonatal hypocalcaemia. Arch Dis Child 1987;62:580-4.neutral phosphate solution to each 100 ml of 8Talmage RV, Cooper CW, Toverud SU. The physiologicalexpressed breast milk, or the use of a preterm significance of calcitonin. In: Peck WA, ed. Bone and mineralformula containing at least 1 mmol/100 ml of research. Vol 1. Amsterdam: Excerpta Medica, 1983:74-143.phosphorus, and 1-75 mmol/100 ml of calcium. 9Sakamoto S, Sakamoto M. Bone collagenase, osteoblasts, and cell mediated bone resorption. In: Peck WA, ed. Bone andSupplementation should start as soon as enteral mineral research. Vol 4. Amsterdam: Elsevier, 1986:49-102.feeds are started, and continue until the infant 0 Mundy GR, Roodman GD. Osteoclast ontogeny and function.achieves a weight of 2 kg or leaves the nursery. A In: Peck WA, ed. Bone and mineral research. Vol 5. Amster-urinary calcium: phosphorus ratio of >1 at the age dam: Elsevier, 1987:209-80. Baron R, Vignery A, Horowitz M. Lymphocytes, macrophagesof 3 weeks is an indication for further supple- and the regulation of bone remodelling. In: Peck WA, ed. Bonementation. For infants receiving preterm formulas, and mineral research. Vol 2. Amsterdam: Elsevier, 1984:milks with higher mineral densities are available 175-243.overseas, and may be introduced in the United 12 Anderson HC. Matrix vesicle calcification: review and update. In: Peck WA, ed. Bone and mineral research. Vol 3. Amster-Kingdom in the near future. Breast milk can be dam: Elsevier, 1985:109-50.supplemented with both calcium and phorphorus 13 Sedman AB, Klein GL, Merritt RJ, et al. Evidence ofusing the previously described method. aluminium loading in infants receiving intravenous therapy. It is hoped that early mineral supplementation N Engl J Med 1985;312:1337-43. 14 Cooper PA, Rothberg AD, Pettifor JM. Early follow-up of verywill result in a reduction in the incidence of low birthweight infants after hospital discharge with respect tometabolic bone disease during the neonatal period, growth and mineral homeostasis. J Pediatr Gastroenterol Nutrand maximise the potential for subsequent bone 1988;7:577-82.growth. s5 Kulkarni PB, Hall RT, Rhodes PG. Rickets in very low birthweight infants. J Pediatr 1980;2:249-52. 16 Lucas A, Brooke OG, Baker BA, Bishop N, Morley R. High alkaline phosphatase activity and growth in preterm neonates.References Arch Dis Child 1989;64:902-9. 17 Greer FR, Lane J, Weiners S, Mazess RB. An accurate and Ziegler E, ODonnel A, Nelson S, Fomon S. Body composition reproducible absorptiometric technioque for determining bone of the reference fetus. Growth 1976;40:329-41. mineral content in newborn infants. Pediatr Res 1983;17:259-62. 2 Pitkin RM, Cruikshank DP, Schauberger CW, Reynolds WA, 8 Chan GM, Mikur L, Hansen JW. Effects of increased calcium Williams GA, Horgis GK. Fetal calciotropic hormones and and phosphorus formulas on bone mineralisation in preterm neonatal calcium homeostasis. Pediatrics 1980;66:77-82. infants. J Pediatr Gastroenterol Nutr 1986;5:444-9. 3 Delvin E, Glorieux F, Salle B, David L, Varenne J. Control of 19 Salle B, Senterre J, Putet G, Rigo J. Effects of calcium and vitamin D metabolism in preterm infants: fetomaternal relation- phosphorus supplementation on calcium retention and fat ships. Arch Dis Child 1982;57:754-7. absorption in preterm infants fed pooled human milk. J Pediatr 4 Wong GL. Skeletal effects of parathyroid hormone. In: Peck Gastroenterol Nutr 1986;5:638-42. WA, ed. Bone and mineral research. Vol 4. Amsterdam: 20 Schanler RJ, Abrams SA, Garza C. Bioavailability of calcium Elsevier, 1986:103-30. and phosphorus in human milk fortifiers and formula for very 5 Cooper U, Anast CS. Circulating immunoreactive parathyroid low birthweight infants. J Pediatr 113:95-100. hormone levels in premature infants and the response to calcium 21 Greer FR, Tsang RC. Calcium, phosphorus, magnesium and therapy. Acta Paediatr Scand 1985;74:669-73. vitamin D requirements for the preterm infant. In: Tsang RC, 6 Cohn VD, Elting JJ. Synthesis and secretion of parathormone ed. Vitamin and mineral requirements in preterm infants. New and secretory I protein by the parathyroid gland. In: Peck WA, York: Marcel Dekker. 1985:99-136. ed. Bone and mineral research. Vol 2. Amsterdam: Elsevier, 1984:1-64. Correspondence to Dr N Bishop, Dunn Nutritional Laboratory, 7 Romagnoli C, Zecca E, Tortorolo G, Diodato A, Fazzini G, Downhams Lane, Milton Road, Cambridge CB4 IXJ.